Michael Ryskin, an analyst from Bank of America Securities, reiterated the Buy rating on Elanco Animal Health (ELAN – Research Report). The associated price target remains the same with $13.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Ryskin has given his Buy rating due to a combination of factors including Elanco’s strong first-quarter performance and promising growth prospects. The company reported sales and earnings that exceeded expectations, leading to an upward revision of its full-year sales guidance. Elanco’s innovation-driven products, such as Zenrelia, Credelio Quattro, and Experior, have shown significant sales contributions, which bolsters confidence in achieving sustained sales growth.
Additionally, potential future catalysts, like the Zenrelia label change and the anticipated approval of the IL-31 antibody, further enhance Elanco’s growth outlook. The company’s ability to navigate macroeconomic challenges and maintain a robust product portfolio supports the attractive risk/reward profile that Ryskin identifies. Consequently, the price objective remains at $13, reflecting a positive view on Elanco’s market position and industry dynamics.
In another report released on April 22, TD Cowen also maintained a Buy rating on the stock with a $12.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELAN in relation to earlier this year.